Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.610
+0.210 (4.77%)
At close: Mar 20, 2026, 4:00 PM EDT
4.610
0.00 (0.00%)
After-hours: Mar 20, 2026, 4:10 PM EDT

Neuphoria Therapeutics Balance Sheet

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2023
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22
Cash & Equivalents
22.1714.2112.6112.123.15
Cash & Short-Term Investments
22.1714.2112.6112.123.15
Cash Growth
410.30%12.71%4.17%-47.72%-
Accounts Receivable
----0.04
Other Receivables
1.110.010.130.434.63
Total Trade Receivables
1.110.010.130.434.68
Other Current Assets
0.110.820.460.81.01
Total Current Assets
23.3915.0413.1913.3328.84
Net Property, Plant & Equipment
-0.110.220.330.47
Other Intangible Assets
4.474.85.476.136.79
Goodwill
8.748.648.698.698.88
Long-Term Investments
----0.08
Other Long-Term Assets
--0.080.08-
Total Assets
36.628.5927.6528.5645.05
Accounts Payable
0.521.152.241.441.92
Accrued Expenses
2.072.951.461.19-
Current Portion of Leases
-0.120.120.110.11
Other Current Liabilities
----0.28
Total Current Liabilities
2.594.223.832.742.31
Long-Term Leases
--0.120.240.37
Other Long-Term Liabilities
4.315.376.213.573.11
Total Long-Term Liabilities
4.315.376.333.813.48
Total Liabilities
6.99.5910.166.555.79
Common Stock
000-150.15
Additional Paid-in Capital
218.32200.19198.48187.558.64
Accumulated Other Comprehensive Income
-2.23-2.85-3.01-3.06-
Retained Earnings
-186.39-178.35-177.98-162.48-119.54
Shareholders' Equity
29.71917.4922.0139.26
Total Liabilities & Equity
36.628.5927.6528.5645.05
Total Debt
-0.120.240.350.48
Net Cash (Debt)
22.1714.0912.3711.7522.67
Net Cash Growth
57.30%13.95%5.27%-48.18%-
Net Cash Per Share
8.538.6914.860.01-
Book Value
29.71917.4922.0139.26
Book Value Per Share
11.4211.7121.020.01-
Tangible Book Value
16.495.563.337.1923.59
Tangible Book Value Per Share
6.343.434.000.00-
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q